Meclizine for Hepatocellular Carcinoma (OPTIM) (H-40370)
OPTIM: A Window of Opportunity Trial With Meclizine in Hepatocellular Carcinoma
Meclizine hydrochloride is an antihistamine widely used for treatment of vertigo and motion sickness. In HCC it has been used for anti-emetic effects, but it is used here as a CAR (constitutive androstane receptor) inverse agonist.
The hypothesis of this study is that meclizine, a CAR inverse agonist, will have a beneficial therapeutic effect in patients with hepatocellular carcinoma who are candidates for surgical resection, ablation or TACE (trans-arterial chemoembolization) by blocking tumorigenesis and inducing apoptosis.